HOECHST MARION ROUSSEL AMARYL ARBITRATION, FIRST UNDER EU MUTUAL RECOGNITION PROCEDURE, "LIKE A DREAM," EMEA MEMBER SAYS; SYSTEM UPTAKE REMAINS SLOW

The first arbitration under the European mutual recognition procedure, involving Hoechst Marion Roussel's Amaryl (glimepiride), "went like a dream," according to EMEA Committee for Proprietary Medicinal Products member David Lyons, MD, Irish Medicines Board. "I think the arbitration went as well as could have been hoped," he reported at a conference organized by the European Federation of Pharmaceutical Industries' Associations in London Sept. 12-13. Lyons did not reveal details of the procedure.